FIGURES

Figures 1(a)-(c): Levels of SPM 7675, SPM 7605 and total degradation products in fesoterodine hydrogen fumarate IR beads (90:10, 85:15 & 80:20 weight % hydroxypropyl methylcellulose – Methocel E5 LV (trade mark): fesoterodine hydrogen fumarate) and the commercial tablet formulation (Xylitol 1 and 2) when stored at 40°C/75%RH.

FIGURE 1(a)



SPM7605 (%)
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
0
2
4
6
8
10
12
Weeks
O xylitol 1
Δ xylitol 2
◇ 80/20
X 85/15
□ 90/10

FIGURE 1(b)



SPM7675 (%)
1.4
1.2
1
0.8
0.6
0.4
0.2
0
0
2
4
6
8
10
12
Weeks
O xylitol 1
Δ xylitol 2
◇ 80/20
× 85/15
□ 90/10

FIGURE 1(c)




Total Impurities (%)
Weeks
O xylitol 1
Δ xylitol 2
◇ 80/20
X 85/15
□ 90/10

FIGURE 2



(a) crystalline fesoterodine hydrogen fumarate
(b) amorphous fesoterodine hydrogen fumarate
(c) HPMC- hypromellose-Methocel E5LV

FIGURE 2a - fingerprint region of FIGURE 2




FIGURE 2b - area for assessment from FIGURES 2 and 2(a)






FIGURE 3




(a) crystalline fesoterodine hydrogen fumarate
(b) amorphous fesoterodine hydrogen fumarate
(c) IR layer from IR beads
(d) HPMC -hypromellose-Methocel E5LV

FIGURE 3a




(a) crystalline fesoterodine hydrogen fumarate
(b) amorphous fesoterodine hydrogen fumarate
(c) (d) and (e) IR layer from IR beads (three different samples showing sample variability)
(f) HPMC-hypromellose-Methocel E5LV

FIGURE 4




(a) crystalline fesoterodine hydrogen fumarate
(b) amorphous fesoterodine hydrogen fumarate
(c) IR layer from 10% MR beads
(d) HPMC-hypromellose-Methocel E5LV

FIGURE 4a




(a) crystalline fesoterodine hydrogen fumarate
(b) amorphous fesoterodine hydrogen fumarate
(c) and (d) IR layer from 10% MR beads (two different samples showing sample variability)
(e) HPMC-hypromellose-Methocel E5LV

FIGURE 5




(a) crystalline fesoterodine hydrogen fumarate
(b) amorphous fesoterodine hydrogen fumarate
(c) IR layer from 20% MR beads
(d) HPMC-hypromellose-Methocel E5LV

FIGURE 5a




(a) crystalline fesoterodine hydrogen fumarate
(b) amorphous fesoterodine hydrogen fumarate
(c) and (d) IR layer from 20% MR beads (two different samples showing sample variability)
(e) HPMC-hypromellose-Methocel E5LV

FIGURE 6




(a) crystalline fesoterodine hydrogen fumarate
(b) amorphous fesoterodine hydrogen fumarate
(c) HPMC-hypromellose- (Methocel E5LV)
(d) Lactose (Pharmatose 110 mesh)

FIGURE 6a - fingerprint region of FIGURE 6




5

FIGURE 6b- area for assessment in FIGURES 6 and 6a




5

FIGURE 7




(a) crystalline fesoterodine hydrogen fumarate
(b) amorphous fesoterodine hydrogen fumarate
(c) 1:9 weight % fesoterodine hydrogen fumarate/HPMC on lactose particles
(d) HPMC-hypromellose- (Methocel E5LV)
(e) Lactose (Pharmatose 110 mesh)

FIGURE 7a




(a) crystalline fesoterodine hydrogen fumarate
(b) amorphous fesoterodine hydrogen fumarate
(c) (d) and (e) 1:9 weight % fesoterodine hydrogen fumarate/HPMC on lactose particles (three different samples showing sample variability)
(f) HPMC-hypromellose- (Methocel E5LV)
(g) Lactose (Pharmatose 110 mesh)

FIGURE 8



(a) crystalline fesoterodine hydrogen fumarate
(b) amorphous fesoterodine hydrogen fumarate
(c) 1:19 weight % fesoterodine hydrogen fumarate/HPMC on lactose particles
(d) HPMC-hypromellose- (Methocel E5LV)
(e) Lactose (Pharmatose 110 mesh)

FIGURE 8a



(a) crystalline fesoterodine hydrogen fumarate
(b) amorphous fesoterodine hydrogen fumarate
(c) (d) and (e) 1:19 weight % fesoterodine hydrogen fumarate/HPMC on lactose particles (three different samples showing sample variability)
(f) HPMC-hypromellose- (Methocel E5LV)
(g) Lactose (Pharmatose 110 mesh)